FDA Converts Tecartus Approval to Full Approval in Mantle Cell Lymphoma Following ZUMA-2 Data

The U.S. Food and Drug Administration has granted traditional approval to brexucabtagene autoleucel (Tecartus), a CAR T-cell therapy developed by Kite Pharma, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The decision converts the therapy’s earlier accelerated approval into a full approval based on confirmatory clinical evidence.

Transition from Accelerated to Traditional Approval

Tecartus was initially approved in July 2020 under the FDA’s accelerated approval pathway for serious or life-threatening conditions. This pathway allows earlier access to therapies based on surrogate endpoints, with a requirement for confirmatory studies to verify clinical benefit.

The latest approval follows submission and review of the final report from the Phase 2 ZUMA-2 trial, which fulfilled a postmarketing requirement (PMR #2). This study evaluated brexucabtagene autoleucel in patients with relapsed or refractory MCL, including a cohort who had not previously received Bruton tyrosine kinase (BTK) inhibitors.

ZUMA-2 Study Design and Endpoints

The confirmatory cohort enrolled 86 patients who were naïve to BTK inhibitor therapy. The primary efficacy endpoint was objective response rate, supported by duration of response with a minimum follow-up of 18 months after the first documented response.

The trial was completed in April 2025, with the final report submitted in October 2025. The FDA review of this supplemental application included data linked to clinical trial identifiers NCT04880434 and NCT02601313.

Labeling Updates and Safety Information

As part of the approval, the FDA authorized updates across multiple sections of the prescribing information, including Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, and Clinical Study Data. The revised labeling incorporates the complete dataset from the ZUMA-2 study and aligns with regulatory requirements for full approval.

Regulatory and Postmarketing Commitments

While this approval fulfills the key postmarketing requirement tied to accelerated approval, the FDA noted that additional postmarketing requirements remain ongoing. The sponsor is required to submit annual status reports detailing progress on these commitments.

The therapy is exempt from pediatric study requirements under the Pediatric Research Equity Act due to its orphan drug designation for this indication.

Clinical Context

Mantle cell lymphoma is a rare and aggressive subtype of non-Hodgkin lymphoma, often associated with poor prognosis in relapsed or refractory settings. CAR T-cell therapies such as brexucabtagene autoleucel offer a targeted immunotherapy approach by engineering a patient’s own T cells to recognize and eliminate malignant B cells.

The conversion to traditional approval confirms the clinical benefit of Tecartus in this patient population and solidifies its role as a treatment option in relapsed or refractory MCL.

Reference

Supplement Approval, STN: BL 125703/464, April 1, 2026 Approval Letter – TECARTUS

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants with Relapsed/​Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2), ClinicalTrials.gov ID NCT04880434, https://clinicaltrials.gov/study/NCT04880434

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants with Relapsed/​Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) (ZUMA-2), ClinicalTrials.gov ID NCT02601313, https://clinicaltrials.gov/study/NCT02601313